Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV-Reference-Cited by-同舟云学术

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Banda Clifford G.¹²³^ORCID,Nkosi Dumisile¹,Allen Elizabeth²⁴,Workman Lesley²⁴,Madanitsa Mwayiwawo⁵⁶,Chirwa Marumbo¹,Kapulula Mayamiko⁵,Muyaya Sharon⁵,Munharo Steven⁵,Tarning Joel⁷⁸^ORCID,Phiri Kamija S.³⁵,Mwapasa Victor³⁵,ter Kuile Feiko O.⁹,Maartens Gary²^ORCID,Barnes Karen I.²⁴^ORCID

Affiliation:

1. Malawi-Liverpool-Wellcome Research Programme, Blantyre, Malawi

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

3. Kamuzu University of Health Sciences (formerly College of Medicine and Kamuzu College of Nursing, University of Malawi), Blantyre, Malawi

4. WorldWide Antimalarial Resistance Network (WWARN), Pharmacology Scientific Group, University of Cape Town, Cape Town, South Africa

5. Training and Research Unit of Excellence, Blantyre, Malawi

6. Department of Clinical Sciences, Malawi University of Science and Technology, Limbe, Malawi

7. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

8. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

9. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Abstract

Dihydroartemisinin-piperaquine, an artemisinin-based combination therapy, has been identified as a promising agent for intermittent preventive treatment of malaria in pregnancy. However, in pregnant women living with HIV (PLWH), efavirenz-based antiretroviral therapy (ART) significantly reduces the plasma exposure of piperaquine.

Funder

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00584-22

Reference37 articles.

1. The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study

2. Impact of malaria during pregnancy on pregnancy outcomes in a Ugandan prospectivecohort with intensive malaria screening and prompt treatment

3. The Effect of HIV Infection on the Risk, Frequency, and Intensity of Plasmodium falciparum Parasitemia in Primigravid and Multigravid Women in Malawi

4. Reduction of Antimalarial Antibodies by HIV Infection Is Associated With Increased Risk of Plasmodium falciparum Cord Blood Infection

5. Prevalence and predictors of placental malaria in human immunodeficiency virus-positive women in Nigeria

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydroartemisinin–piperaquine for prevention of malaria in pregnant women living with HIV;The Lancet;2024-01

2. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin–piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial;The Lancet;2024-01

3. Erratum for Banda et al., “Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV”;Antimicrobial Agents and Chemotherapy;2023-01-24